Operation Warp Speed's Moncef Slaoui on the n...

Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Axios cofounder and CEO Jim VandeHei joins Axios Re:Cap senior producer Naomi Shavin to talk about what journalists got right a ...  Show more

Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major ...  Show more

Americans fortunate enough to receive vaccines right now, outside of clinical trials, are getting ones made by either Pfizer or Moderna. But newly released data from Novavax and Johnson & Johnson suggests that more vaccines could be on the way. Dan digs into the news and why it m ...  Show more

On the same day the COVID-19 death toll surpassed 300,000 in the United States, the first vaccines are being administered, finally giving millions of Americans hope for a better future and a return to normalcy. We explore how officials expect to deliver a safe and effective vacci ...  Show more

From the start of the pandemic, the Trump administration said it was committed to ordering and stockpiling enough potential vaccine doses to end the outbreak in the United States as quickly as possible.

But new reporting from The Times has revealed that Pfizer, the maker ...

It’s a dark time in the struggle with the coronavirus, particularly in the United States, where infections and hospitalizations have surged.

But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine ...